Within Major Pharmaceutical Preparations industry Actavia Life Sciences Inc booked the highest Quick Ratio than Actavia Life Sciences Inc in the second quarter 2024. While total ranking remained the same in the Q2 2024 compared to the first quarter 2023 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents RASP�s has?
What are RASP�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RASP Quick Ratio	(Mar 31 2024) Q2	(Dec 31 2023) Q1	(Sep 30 2023) Q4	(Jun 30 2023) Q3	(Mar 31 2023) Q2
Y / Y Current Liabilities Change	16.01 %	23.04 %	-31.89 %	-8.64 %	-11.55 %
Y / Y Cash & cash equivalent Change	-	-59.66 %	90.5 %	-76.49 %	-92.09 %
Quick Ratio MRQ	-	0.01	0.04	0	0
RASP's Total Ranking	#	#	#	#	#
Seq. Current Liabilities Change	4.73 %	3.81 %	20.89 %	-11.73 %	11.08 %
Seq. Cash & cash equivalent Change	-	-74.42 %	2933.41 %	11.3 %	-95.33 %

Quick Ratio second quarter 2024 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	#
Healthcare Sector	#
Overall Market	#

Quick Ratio Statistics
High	Average	Low
0	0	0

Financial Statements
Actavia Life Sciences Inc 's Current Liabilities	$ 2 Millions	Visit RASP's Balance sheet
Actavia Life Sciences Inc 's Cash & cash equivalent	$ 0 Millions	Visit RASP's Balance sheet
Source of RASP's Sales		Visit RASP's Sales by Geography

Cumulative Actavia Life Sciences Inc 's Quick Ratio

RASP's Quick Ratio for the trailling 12 Months

RASP Quick Ratio	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months	(Sep 30 2023) 12 Months	(Jun 30 2023) 12 Months	(Mar 31 2023) 12 Months
Y / Y Current Liabilities TTM Growth	-4.86 %	-11.09 %	-22.74 %	-10.72 %	-19.02 %
Y / Y Cash & cash equivalent TTM Growth	-3.02 %	-21.23 %	28.49 %	29.93 %	-10.08 %
Quick Ratio TTM	0.01	0.01	0.02	0.01	0.01
Total Ranking TTM	# 3830	# 3830	# 3809	# 3811	# 2755
Seq. Current Liabilities TTM Growth	3.95 %	5.39 %	-11.49 %	-1.88 %	-2.86 %
Seq. Cash & cash equivalent TTM Growth	-2.25 %	-22.3 %	38.89 %	-8.07 %	-20.6 %

Quick ratio ranking by company, industry and sector >> Back to RASP Financial Strength Comparisons >> Go to Compare RASP Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the rise in Current Liabilities in the Q2 2024 to $2.23 millions, cumulative Quick Ratio remained unchanged at 0.01 below the Actavia Life Sciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 492 other companies have achieved higher Quick Ratio than Actavia Life Sciences Inc . While overall ranking is unchanged compared to the previous 12 months at no. 3830.

Explain Quick Ratio?
How much Cash & cash equivalents RASP�s has?
What are RASP�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 493
Healthcare Sector	# 1020
Within the Market	# 3830

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.49	0.17	0.01
(Dec 31 2017)		(Dec 31 2020)

Companies with similar Quick Ratio in the quarter ending Mar 31 2024, within Major Pharmaceutical Preparations Industry

Quick Ratio

Mar 31 2024 MRQ Cash & cash equivalent

Mar 31 2024 MRQ Current Liabilities

Date modified: 2026-09-08T15:11:16+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.